News

Summa Equity Acquires Cleanroom Provider G-CON Manufacturing

July 22, 2021

Summa Equity has acquired a majority stake in G-CON Manufacturing, a prefabricated cleanroom provider.

Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa

July 22, 2021

Pfizer Inc. and BioNTech SE announced the signing of a letter of intent with The Biovac Institute Ltd to manufacture the Pfizer-BioNTech COVID-19 vaccine for distribution within the African Union.

Catalent Biologics Launches New Cell Line Expression Technology

July 22, 2021

Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.

Sinovac’s Eupolio Vaccine Gains Market Authorization in China

July 22, 2021

Sinovac Biotech’s Eupolio vaccine, a Sabin inactivated poliovirus vaccine (sIPV), has gained marketing authorization in China.

Exscientia and GT Apeiron Form Strategic R&D Collaboration Agreement

July 22, 2021

Exscientia and GT Apeiron Therapeutics have entered into a strategic R&D oncology collaboration agreement.

Advanz Pharma Launches Generic Lanreotide in Germany

July 22, 2021

Specialty pharmaceutical company, Advanz Pharma, has launched a generic version of lanreotide, MYTOLAC, in Germany.

Catalent Invests $100 Million to Expand European Biologics Manufacturing Capabilities

July 22, 2021

Catalent commences the first phase of a $100-million expansion program Anagni site to increase its manufacturing capabilities for biologics drug substance.

EC Grants Marketing Authorization for bluebird bio’s Gene Therapy SKYSONA

July 22, 2021

The European Commission has granted marketing authorization to bluebird bio for its gene therapy SKYSONA for the treatment of early CALD.

Samsung Biologics Partners with Kineta for Anti-VISTA Antibody Immunotherapy

July 21, 2021

Samsung Biologics and Kineta have entered into a strategic partnership for drug product manufacturing services and to support an IND filing of a novel antibody therapeutic.

BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Manufacturing Facility

July 21, 2021

BioNTech will acquire a TCR cell therapy R&D platform as well as a manufacturing facility in Gaithersburg, Md., from Kite, a Gilead company.